Comparison of cefadroxil and cephalexin in the treatment of community-acquired pneumonia.

Abstract

Thirty-four patients with community-acquired acute pneumonias were treated in a prospective, randomized trial with either cefadroxil, 500 mg twice daily, or cephalexin, 250 mg four times daily. In both groups of patients, the presence of chronic illnesses predisposing to pneumonia was common. Streptococcus pneumoniae was isolated from 65% of the initial sputum specimens, and most illnesses were of mild to moderate severity. All 19 cases treated with cefadroxil and all 15 cases treated with cephalexin were clinically cured, and adverse reactions to the medications were minimal. The success of these regimens suggests that outpatient use of oral cephalosporin therapy may be an appropriate treatment of patients with mild or moderate community-acquired pneumonia.

• Authors: M J Blaser, B D Klaus, J A Jacobson, E Kasworm, F M LaForce
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 24 Issue 2 Pg. 163-7 (Aug 1983) ISSN: 0066-4804 [Print] United States
• PMID: 6605713 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cefadroxil
• Cephalexin

Topics

• Adult
• Aged
• Cefadroxil (adverse effects, therapeutic use)
• Cephalexin (adverse effects, therapeutic use)
• Female
• Haemophilus influenzae (isolation & purification)
• Humans
• Male
• Middle Aged
• Pneumonia (drug therapy, etiology)
• Streptococcus pneumoniae (isolation & purification)